Vaporeon

Skyridge · #H31 · Rare Holo

CARDMARKET →

€750.00

↑ 0.2% 30D

Graded

PSA 9€1,620

PSA 10€3,888

Composite

4.5

Updated 3 days agoEU 171% above US

Buy range€179.81 – €235.14Above market

All prices and projections are for Near Mint English-language cards. Other conditions and languages may vary significantly.

Price history

Ungraded NM PSA 9 PSA 10

Investment thesis

Sub-score breakdown · ROI projections

4.5

SCORE / 10

Liquidity

7.8

Scarcity

—

Era potential

8.9

Friction

3.1

Hold-Raw · 5Y Outlook▲ PRIMARY

+•••%

Available with Pro

Grade or sell · per-card

Free account

See if grading this card pays.

How is this scored?

The composite score (0–10) blends signals across trust, set tier, era, liquidity, and price. The four sub-scores shown above (Liquidity, Scarcity, Era CAGR, Friction) describe each card across complementary axes; they share inputs with the composite but use different formulas. The Friction sub-score (added 2026-05-11) combines liquidity, price-spread stability, era maturity, and affordability minus a flat marketplace-fee proxy. The era-benchmark ROI numbers project returns based on the card's release era — they're not card-specific predictions. Limitations: the score is a relative ranking heuristic, not a forecast. Prices are snapshots and can drift between refreshes — always verify externally before buying.

Pop report

PSA 10

PSA 9

PSA 8

Total graded

No PSA pop data on file for this card yet.

OVERVIEW

Investment summary

Skyridge's Vaporeon (#H31) currently trades at €750.00 in the raw market. Its 30-day price movement has remained flat (+0.2%). By market value it ranks #7 of 191 in Skyridge — the 95th percentile of the set. With recent sales tracked over the trailing 180 days, liquidity is rated medium. Read together, a top-tier ranking in Skyridge alongside flat 30-day momentum frames where Vaporeon sits in the set's pricing structure — context worth weighing against the set's stronger names before timing an entry. Market data is informational only and does not constitute investment advice.